Sangamo Therapeutics Announces Chief Financial Officer Succession
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Piper Jaffray Remains Sidelined on Sangamo Biosciences (SGMO) Following 4Q Report
February 28, 2017 12:01 PM ESTPiper Jaffray reiterated a Neutral rating and $5.00 price target on Sangamo BioSciences (NASDAQ: SGMO) following the company's 4Q earnings report. Sangamo reported 4Q16 revenues of $8.9M, slightly above projections, and opex of $18.8M, slightly below projections.
Analyst Charles Duncan commented, "Today Sangamo reported 4Q16 financial... More
